The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
|Articles|February 4, 2015
- Gastrointestinal Cancers (Issue 4)
- Volume 4
- Issue 1
FOLFOXIRI plus Bevacizumab for Metastatic Colorectal Cancer
Author(s)Chiara Cremolini, MD
Chiara Cremolini, MD, discusses the phase III TRIBE trial, which compared FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as for patients with metastatic colorectal cancer.
Advertisement
Chiara Cremolini, MD, a medical oncologist at the Tuscan Tumor Institute in Pisa, Italy, discusses updated results from the phase III TRIBE trial, which compared FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as a first-line treatment for patients with metastatic colorectal cancer (mCRC).
Clinical Pearls:
- The study was used to compare progression-free and overall survival rates for patients with mCRC using FOLFOXIRI plus bevacizumab and FOLFIRI with bevacizumab.
- Patients in the FOLFOXIRI arm achieved an overall survival rate of 29.8 months, versus 25.8 months for patients in the FOLFIRI arm.
- 1 out of 4 ​patients who were given FOLFOXIRI plus bevacizumab had a survival rate of 5 years, as compared to 1 out of 8 patients who were treated with FOLFIRI plus bevacizumab.
Articles in this issue
over 11 years ago
Expert Investigators Discuss Emerging Therapies for GI Cancersover 11 years ago
Predictors of Toxicity in Colon Cancer Treatment Identifiedover 11 years ago
Many Biliary Tract Cancers Harbor Actionable Mutationsover 11 years ago
Safety of Regorafenib Confirmed in Patients With mCRC and High PFSover 11 years ago
Chemotherapy Treatment in Gastric Cancerover 11 years ago
Pembrolizumab in Advanced Gastric Cancer Treatmentover 11 years ago
Onartuzumab for Gastroesophageal AdenocarcinomaAdvertisement
Related to this article
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end point but reduced neurotoxicity.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5